| Therapeutic | Alemtuzumab |
| Target | CD52 |
| Heavy Chain | QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK |
| 100% seqID Fv Structure | 1bey [Fvs: HL], 1ce1 [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 1bey [Fvs: HL] |
| 100% seqID Structure | 1ce1 [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2000 |
| INN Year Recommended | 2001 |
| Companies Involved | Bayer HealthCare Pharmaceuticals Inc., Dana-Farber Cancer Institute, German CLL Study Group, Ohio State University Comprehensive Cancer Center, Sanofi, Sanofi Oncology, University of Cologne, University of Cambridge |
| Conditions Approved | Chronic lymphocytic leukaemia, Multiple sclerosis |
| Conditions Active | Lymphoma, T-cell prolymphocytic leukaemia |
| Conditions Discontinued | Rheumatoid arthritis, Diffuse large B cell lymphoma, Graft-versus-host disease, Sezary syndrome, T-cell lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
